Why Is Mounjaro Going Up in Price in the UK?

The myth worth clearing up first: this isn't pharmacies inflating margins

A lot of people assume that if Mounjaro's price has jumped, someone in the supply chain is profiteering. That's a reasonable instinct, but it isn't what happened. Eli Lilly set a new UK list price from 1 September 2025, and that list price is what every licensed pharmacy in the country pays to source the medicine through the authorised supply chain. The change was widely reported in August 2025 and is a matter of public record. Private providers then price around that cost, which is why the figures you see across the market moved in broadly the same direction at roughly the same time.

It's also worth separating the Mounjaro price story from the NHS conversation. On the NHS, tirzepatide is commissioned under NICE technology appraisal TA1026, and NHS procurement pricing operates separately from private list prices, so the rise in private costs does not directly translate to a change in what the NHS pays or who qualifies. If you want to understand how the NHS and private pricing interact, that's covered separately.

The short version: private Mounjaro prices went up because the manufacturer raised its UK list price, and if you're wondering whether the cost of Mounjaro is going up further, that question is explored in detail on its own page. There is no shortcut around that through the legitimate supply chain.

What typical private prices include (and what they sometimes don't

Since September 2025, private Mounjaro has typically been priced somewhere between £149 and £375 per month, varying by dose and provider) figures that have been widely reported and reflect the post-increase market. Those headline numbers can look very different depending on what is bundled in.

Some providers list a figure that covers the medicine only. Consultation fees, prescription charges, delivery and any ongoing clinical support may then arrive as separate line items. For a medicine that requires dose titration, a prescriber review before every repeat, and genuine aftercare if side effects arise, those additions are not optional extras, they are part of safe treatment.

You can read a fuller breakdown of how Mounjaro pricing works across the private market, including what questions to ask any provider before committing. The detail on prices going up covers the Lilly announcement in more depth if you want the background.

At nume, one price covers the consultation, the prescription, the medicine, and free next-working-day delivery. There are no add-on fees. We are not the cheapest option on the market, and that is a deliberate choice: our clinical infrastructure, the prescriber time involved in every review, and the aftercare we provide seven days a week are all priced in from the start. Current treatment pricing is shown on our treatment page.

Why 'cheapest Mounjaro' is not the right search to run

For a Prescription-Only Medicine sourced through a clinical pathway, price is genuinely the wrong place to start your comparison. The MHRA has warned publicly about counterfeit weight-loss pens sold online, fake pens have been seized in large quantities, and some have been found to contain insulin rather than tirzepatide. Sellers offering these medicines without a prescription, via social media, or at prices well below the current market should be treated as a serious red flag. You can report suspect sellers at the MHRA's Yellow Card scheme.

The right questions are: can I verify this pharmacy on the GPhC register? Does a real prescriber review my case before every order? Is the medicine coming through the licensed UK supply chain? You can verify any online pharmacy at the GPhC pharmacy register; nume's premises registration is 9012878. Those checks cost nothing. The consequences of skipping them can be significant.

If you want to understand more about how Mounjaro works as a treatment (the mechanism, the clinical evidence, who it is licensed for) that's all covered on our main Mounjaro page. Our clinical team oversees every prescription we issue.

What comes next on price, and a realistic picture

Nobody can say with certainty whether Mounjaro's price will rise again, stay flat, or eventually fall as the market matures. The honest answer is that the September 2025 increase was the first significant list-price movement since UK launch, and manufacturer pricing for branded medicines can move again at any time. Some commentators expect increased competition among GLP-1 medicines to create downward pressure over the medium term; others point to sustained demand as a counterweight. There is no reliable forecast to give you.

What is knowable is the direction of the last change and why it happened, which this page has set out. You can also read about when the price changed and what was announced, or explore the full background on why the price went up if you want more context before deciding on next steps. And if you're weighing whether treatment makes sense for you right now, our weight-loss treatment overview explains the options available through nume.